Sponsor & Developer Portfolio
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Clinical development pipeline, platform architecture, and registered trial tracking for Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair vaccine candidates.
1
Candidates
1
Target Diseases
1
Linked Studies
Development Phase Distribution
Phase 1 Clinical Trial: 1
Platform Technologies
Biological (unspecified platform): 1
Target Pathogens & Indications
COVID-19
Vaccine Pipeline Candidates (1)
Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.
Phase 1 Clinical Trial
ctgov-covid-19-therapeutic-biologic-mix-novavax-covid-19-vaccine-plus-
COVID-19 Therapeutic Biologic Mix - NOVAVAX COVID-19 VACCINE plus BCG Vaccine Mix for percutaneous use
Target: COVID-19
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2026-11-18 (registry estimate)
Explore Other Vaccine Developers & Sponsors
Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.